Acurx Pharmaceuticals (ACXP) Profit After Tax (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has 7 years of Profit After Tax data on file, last reported at -$1.7 million in Q1 2026.

• Quarterly Profit After Tax rose 21.79% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.5 million (up 36.85% YoY) and the FY2025 annual result came in at -$8.0 million, up 43.51% from the prior year.
• Profit After Tax slipped to -$1.7 million in Q1 2026, from -$1.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.6 million in Q4 2025 to a low of -$5.1 million in Q4 2023.
• A 5-year average of -$3.0 million and a median of -$2.8 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 81.11% — and 2025, when it jumped 50.91%.
• Tracing ACXP's Profit After Tax over 5 years: stood at -$3.3 million in 2022, then plunged by 56.86% to -$5.1 million in 2023, then surged by 45.61% to -$2.8 million in 2024, then surged by 43.26% to -$1.6 million in 2025, then slipped by 6.51% to -$1.7 million in 2026.
• The last three Profit After Tax figures came in at -$1.7 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.